Delving into the Latest Updates on HB-adMSCs(Hope Biosciences) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

Allogeneic Hope Biosciences adipose-derived mesenchymal stem cells(Hope Biosciences)

Target-

Mechanism

Stem cell replacements

Therapeutic Areas

Immune System DiseasesNervous System DiseasesEndocrinology and Metabolic Disease+ [3]

Active Indication

Juvenile Idiopathic ArthritisParkinson DiseaseAcute Kidney Injury+ [1]

Inactive Indication

COVID-19Pancreatic Cancer

Originator Organization

Hope Biosciences LLCStartup

Active Organization

Hope Biosciences LLCStartup

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This study aims to investigate, through the collection of valid scientific evidence necessary to determine safety and effectiveness, the potential use of Allogeneic Hope Biosciences Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) to prevent progression of trauma-induced Acute Kidney Injury (AKI).

Start Date01 May 2025

Sponsor / Collaborator

Hope Biosciences LLCStartup

[+3]

NCT06623240

/ Not yet recruitingPhase 2

A Randomized, Double-Blind, Phase 2, Efficacy and Safety Cross-Over Study of Allogeneic HB-adMSCs vs Placebo for the Treatment of Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis

Methodology: Randomized, double-blind, AB/BA cross-over study with a washout period of 12 weeks.
Treatment Duration: 8 weeks per group
General Objectives: To assess the efficacy and safety of multiple intravenous infusions of allogeneic HB-adMSCs by improving signs and symptoms of juvenile idiopathic arthritis in this subject population.
Number of Subjects: 66 (6 subjects in Cohort 1 and 60 subjects in Cohort 2)
Indication: Juvenile Idiopathic Arthritis

Start Date01 Mar 2025

Sponsor / Collaborator

Hope Biosciences LLCStartup

NCT04995081

/ Active, not recruitingPhase 2IIT

A Randomized, Double-Blind, Single Center, Phase 2, Efficacy and Safety Study of Allogeneic HB-adMSCs Vs Placebo for the Treatment of Patients with Parkinson's Disease

This is a randomized, double-blind, single center, phase 2 study to assess efficacy and safety of multiple allogeneic HB-adMSCs vs Placebo for the treatment of Parkinson's disease.

Start Date16 Jul 2021

Sponsor / Collaborator

Hope Biosciences LLCStartup

100 Clinical Results associated with HB-adMSCs(Hope Biosciences)

Login to view more data

100 Translational Medicine associated with HB-adMSCs(Hope Biosciences)

Login to view more data

100 Patents (Medical) associated with HB-adMSCs(Hope Biosciences)

Login to view more data

100 Deals associated with HB-adMSCs(Hope Biosciences)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Kidney Injury	Phase 2	US	Hope Biosciences LLCStartup	01 May 2025
Burns	Phase 2	US	Hope Biosciences LLCStartup	01 May 2025
Juvenile Idiopathic Arthritis	Phase 2	US	Hope Biosciences LLCStartup	01 Mar 2025
Parkinson Disease	Phase 2	US	Hope Biosciences LLCStartup	16 Jul 2021
COVID-19	Phase 2	US	Hope Biosciences LLCStartup	14 May 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04362189 (CTgov)	Phase 2	COVID-19	48	HB-adMSC (HB-adMSCs)	wbmjqygeql(wzgtryvwoa) = ospmmcwtdo dwjxyjjscz (vttsdgadwo, lksyuidkeo - nxapivhqqa) View more	-	25 Jul 2023
				Placebo (Placebo)	wbmjqygeql(wzgtryvwoa) = vdqegkoevg dwjxyjjscz (vttsdgadwo, pvwtblqjll - eaathaghhd) View more
NCT04348435 (CTgov)	Phase 2	COVID-19	53	HB-adMSCs (Allogeneic HB-adMSCs 200MM)	ksqwshpoct(xqidcsalag) = oxedqttvnj cdwityzmxc (vqxwuwsbst, drthmmqjbh - epyfekjfxf) View more	-	17 Nov 2022
				HB-adMSCs (Allogeneic HB-adMSCs 100MM)	ksqwshpoct(xqidcsalag) = usckfdeurx cdwityzmxc (vqxwuwsbst, vfinzbjzlp - qdhluawwwo) View more